Author

E. Office

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2

Frequent Co-Authors

E. O. Johnson· 2 shared T. Kawate· 2 shared A. Golas· 1 shared B. K. Hubbard· 1 shared C. E. Moss· 1 shared C. Gallo· 1 shared C. M. Sassetti· 1 shared C. Trujillo· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

E. O. Johnson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A large-scale chemical-genetic strategy to design antimicrobial combination chemotherapy for Mycobacterium tuberculosis

E. O. Johnson, E. Office, T. Kawate, M. Orzechowski, D. T. Hung

This paper identifies two synergistic EfpA inhibitors for tuberculosis that exhibit collateral sensitivity, demonstrating a strategy for designing antimicrobial combinations using chemical-genetic interactions.

bioRxiv · Sep 27, 2019 · PreprintMicrobiology

Large-scale chemical-genetics yields new Mycobacterium tuberculosis inhibitor classes

E. O. Johnson, E. LaVerriere, M. Stanley, E. Office, E. Meyer, T. Kawate, J. Gomez, R. E. Audette, N. Bandyopadhyay, N. Betancourt, K. Delano, I. Da Silva, J. Davis, C. Gallo, M. Gardner, , Schnappinge

This study uses a novel chemical-genetics screening strategy to identify new inhibitors of Mycobacterium tuberculosis, revealing novel compound classes targeting previously unexplored bacterial targets.

bioRxiv · Jan 16, 2019Microbiology